Subcutaneous envafolimab monotherapy in patients with advanced defective mismatch repair/microsatellite instability high solid tumors

BACKGROUND: Monoclonal antibodies targeting programmed death ligand 1 (PD-L1) signaling currently approved for defective mismatch repair (dMMR)/microsatellite instability high (MSI-H) tumors must be delivered by intravenous infusion. Envafolimab, a humanized single-domain anti-PD-L1 antibody fused t...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
izdano v:J Hematol Oncol
Main Authors: Li, Jian, Deng, Yanhong, Zhang, Weijie, Zhou, Ai-Ping, Guo, Weijian, Yang, Jianwei, Yuan, Ying, Zhu, Liangjun, Qin, Shukui, Xiang, Silong, Lu, Haolan, Gong, John, Xu, Ting, Liu, David, Shen, Lin
Format: Artigo
Jezik:Inglês
Izdano: BioMed Central 2021
Teme:
Rapid Communication
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC8218452/
https://ncbi.nlm.nih.gov/pubmed/34154614
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s13045-021-01095-1
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki